These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2923478)

  • 1. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.
    Wonke B; Hoffbrand AV; Aldouri M; Wickens D; Flynn D; Stearns M; Warner P
    Arch Dis Child; 1989 Jan; 64(1):77-82. PubMed ID: 2923478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).
    Pippard MJ; Jackson MJ; Hoffman K; Petrou M; Modell CB
    Scand J Haematol; 1986 May; 36(5):466-72. PubMed ID: 3738427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
    Gallant T; Boyden MH; Gallant LA; Carley H; Freedman MH
    Am J Med; 1987 Dec; 83(6):1085-90. PubMed ID: 3503576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
    Cases A; Kelly J; Sabater J; Campistol JM; Torras A; Montoliu J; López I; Revert L
    Clin Nephrol; 1988 Apr; 29(4):176-8. PubMed ID: 3365862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vision and hearing during deferoxamine therapy.
    Cohen A; Martin M; Mizanin J; Konkle DF; Schwartz E
    J Pediatr; 1990 Aug; 117(2 Pt 1):326-30. PubMed ID: 2380834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
    Cases A; Kelly J; Sabater F; Torras A; Griño MC; Lopez-Pedret J; Revert L
    Nephron; 1990; 56(1):19-23. PubMed ID: 2234245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
    Olivieri NF; Buncic JR; Chew E; Gallant T; Harrison RV; Keenan N; Logan W; Mitchell D; Ricci G; Skarf B
    N Engl J Med; 1986 Apr; 314(14):869-73. PubMed ID: 3485251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
    Chao YH; Wu KH; Lin CY; Tsai MH; Peng CT; Wu HP; Lin CD
    Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major].
    Girot R; Triadou P; Bories D; Jeannel F; Thevenin M; Rymer JC
    Nouv Rev Fr Hematol (1978); 1982; 24(5):281-7. PubMed ID: 7167380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth.
    Chan YL; Li CK; Pang LM; Chik KW
    Clin Radiol; 2000 Aug; 55(8):610-4. PubMed ID: 10964732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
    Kontzoglou G; Koussi A; Tsatra J; Noussios G; Vital V; Sagarakis G; Athanassiou M
    Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.